Shopping Cart
- Remove All
- Your shopping cart is currently empty
GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
2 mg | $43 | In Stock | |
5 mg | $70 | In Stock | |
10 mg | $125 | In Stock | |
25 mg | $235 | In Stock | |
50 mg | $348 | In Stock | |
100 mg | $518 | In Stock | |
1 mL x 10 mM (in DMSO) | $68 | In Stock |
Description | GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2. |
Targets&IC50 | CB2:63 nM(EC50) |
In vitro | GW842166X demonstrates comparable potency and efficacy for rat and human recombinant CB2 receptors, with EC50 values of 91 nM and 63 nM, respectively. [1] It exhibits full agonist activity in cyclase assays with an EC50 of 133 nM and an Emax of 101%, and weak agonist activity in FLIPR assays with an EC50 of 7.780 μM and an Emax of 84%. [2] |
In vivo | GW842166X has an oral bioavailability of 58% and a half-life of 3 h when dosed orally in the rat. GW842166X has extremely high potency with an oral ED50 of 0.1 mg/kg and shows full reversal of hyperalgesia at 0.3 mg/kg in the FCAa model of inflammatory pain. [1] GW842166X orally administrated at a dose of 15 mg/kg for 8 days produced a significant reversal of the CCI induced decrease in paw withdrawal threshold in a rat model of neuropathic pain. [3] |
Molecular Weight | 449.25 |
Formula | C18H17Cl2F3N4O2 |
Cas No. | 666260-75-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 16 mg/mL (35.6 mM) | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.